- Home
- IBAC vs ELUT Comparison
IBAC vs ELUT Comparison
Compare IBAC & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBAC
- ELUT
- Stock Information
- Founded
- IBAC 2020
- ELUT 2015
- Country
- IBAC United States
- ELUT United States
- Employees
- IBAC N/A
- ELUT N/A
- Industry
- IBAC
- ELUT Medical Specialities
- Sector
- IBAC
- ELUT Health Care
- Exchange
- IBAC Nasdaq
- ELUT Nasdaq
- Market Cap
- IBAC 159.4M
- ELUT 128.3M
- IPO Year
- IBAC 2024
- ELUT 2020
- Fundamental
- Price
- IBAC $10.21
- ELUT $3.22
- Analyst Decision
- IBAC
- ELUT Strong Buy
- Analyst Count
- IBAC 0
- ELUT 2
- Target Price
- IBAC N/A
- ELUT $10.00
- AVG Volume (30 Days)
- IBAC 5.0K
- ELUT 37.7K
- Earning Date
- IBAC 01-01-0001
- ELUT 03-06-2025
- Dividend Yield
- IBAC N/A
- ELUT N/A
- EPS Growth
- IBAC N/A
- ELUT N/A
- EPS
- IBAC 0.22
- ELUT N/A
- Revenue
- IBAC N/A
- ELUT $24,782,000.00
- Revenue This Year
- IBAC N/A
- ELUT $3.88
- Revenue Next Year
- IBAC N/A
- ELUT $34.52
- P/E Ratio
- IBAC $45.84
- ELUT N/A
- Revenue Growth
- IBAC N/A
- ELUT N/A
- 52 Week Low
- IBAC $9.93
- ELUT $2.28
- 52 Week High
- IBAC $10.50
- ELUT $5.24
- Technical
- Relative Strength Index (RSI)
- IBAC N/A
- ELUT 55.09
- Support Level
- IBAC N/A
- ELUT $2.83
- Resistance Level
- IBAC N/A
- ELUT $3.00
- Average True Range (ATR)
- IBAC 0.00
- ELUT 0.26
- MACD
- IBAC 0.00
- ELUT 0.09
- Stochastic Oscillator
- IBAC 0.00
- ELUT 91.01
About IBAC IB Acquisition Corp. Common Stock
IB Acquisition Corp is a blank check company.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.